Skip to main content
. 2020 May 18;15(5):e0233176. doi: 10.1371/journal.pone.0233176

Fig 4. Effects of levosimendan on intracellular cAMP and cGMP in human PAs and PVs.

Fig 4

A): cAMP: ■ PA: control (n = 5); ■ PA: 1 μM levosimendan (n = 4); ■ PA: 100 μM levosimendan (n = 7); ■ PV: control (n = 6); ■ PV: 1 μM levosimendan (n = 4); ■ PV: 100 μM levosimendan (n = 8). B): cGMP: ■ PA: control (n = 5); ■ PA: 1 μM levosimendan (n = 3); ■ PA: 100 μM levosimendan (n = 6); ■ PV: control (n = 3); ■ PV: 1 μM levosimendan (n = 3); ■ PV: 100 μM levosimendan (n = 6). A/B: Statistics was performed by the Mann-Whitney U test. P<0.05 are considered as significant: * p<0.05 or ** p<0.01.